RDIA
ATYR

RE Dickinson Investment Advisors’s aTyr Pharma ATYR Stock Holding History

RE Dickinson Investment Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300
Closed -$1K – 427
2022
Q4 		$1K Hold
300
– – ﹤0.01% 379
2022
Q3 		$1K Hold
300
– – ﹤0.01% 252
2022
Q2 		$1 Hold
300
– – ﹤0.01% 281
2022
Q1 		$2K Hold
300
– – ﹤0.01% 265
2021
Q4 		$2K Buy
+300
New +$2.5K ﹤0.01% 270

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RE Dickinson Investment Advisors's ATYR Position: Q1 2023 in Review

RE Dickinson Investment Advisors sold out of aTyr Pharma (ATYR) in Q1 2023, closing a stake of 300 shares — an estimated $1K sold.

RE Dickinson Investment Advisors first reported a position in ATYR in Q4 2021 and held it in 5 quarters. The position peaked at $2K in Q1 2022. 37 funds tracked by Wall St. Rank hold ATYR as of Q1 2023.

  • RE Dickinson Investment Advisors reported no remaining aTyr Pharma position as of Q1 2023 after selling out during the quarter.
  • RE Dickinson Investment Advisors sold 300 aTyr Pharma shares in Q1 2023, an estimated $1K.
  • RE Dickinson Investment Advisors first reported a position in aTyr Pharma in Q4 2021 and held it in 5 quarters.
  • RE Dickinson Investment Advisors's aTyr Pharma position peaked at $2K in Q1 2022.
  • 37 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2023.

Based on RE Dickinson Investment Advisors's 13F filing for Q1 2023, filed 8 May 2023.